About the Company
Fresenius Kabi Oncology Limited is a public company primarily operating in the field of Research & Development and manufacturing of world-class oncology drugs. The company strives to provide state-of-the-art third generation chemotherapeutic drugs right from development to manufacturing & marketing across the globe. It is fast emerging as a leading player in oncology generics on the strength of its comprehensive product portfolio of injectables, oral cytotoxics, cytostatics, intermediates and Active Pharmaceutical Ingredients (APIs).
Fresenius Kabi Oncology is the subsidiary of Fresenius Kabi AG, Germany. Fresenius Kabi Oncology specializes in the manufacturing of anti-cancer (oncology) drugs to treat chronically and critically ill cancer patients. As a part of the globally reputed Fresenius Healthcare Group, it plays a pivotal role in patient care, both within and outside hospitals, to efficaciously carry forward its mission of “caring for life”.
The company has two manufacturing plants. The first is in Himachal Pradesh and the second is in West-Bengal.
Industry Analysis
According to a market report, the global cancer therapy market was valued at 9.53 lakh cr in 2018 and estimated to be valued at 15.44 lakh cr by 2024, witnessing a CAGR growth of 8.37%.
Cancer therapy is a highly competitive market, consists of several major players who dominate the market. With the use of technology, a lot of mid and small-sized companies are giving very good competition at a very attractive price.
Indian Drugs are exported to more than 200 countries around the world and the USA is the key market. Approximately 30% of the drugs exported to the USA in 2018.
| Total Available Shares: | 1000 |
| Face Value: | ₹ 1 Per Equity Share |
| ISIN: | INE575G01010 |
| Lot Size: | 100 Shares |
| Current Unlisted Share Price: | ₹ 60 Per Equity Share |
| Retail Discount: | Bulk Deal (1%) |
| Year | Revenue | EBITDA | OPM | PAT | NPM | Equity | EPS |
| 2018 | 701 | 158 | 23% | 19.38 | 3% | 1.702 | 1.13 |
| 2019 | 734 | 131 | 18% | -53.92 | -7% | 1.702 | -3.17 |
You must be logged in to post a comment.
Copyright © 2018-2021 UnlistedZone.com.
All Rights Reserved.
828, Sector 2B, Vasundhara, Delhi-NCR, India 201012
Market Wizard
Important information for the shareholders:
1. Fresenius Kabi Oncology in the year 2018 has filed a case in NCLT for capital reduction.
They have proposed to reduce the number of shares from 17,02,47,857 equity shares of INR 1 (Indian rupee one) to 16,52,32,882 equity shares of INR 1 (Indian rupee one) each by canceling and extinguishing in the aggregate, approximately 2.95% (two point nine five percent) of the total issued, subscribed and paid-up share capital of the Company, consisting of 50,14,975.
2. As per the annual report 2018-19, total shares held by promoters were 97.05% and minority shareholders were 2.95%.
3. So, the company has given exit to the minority shareholders by paying Rs. 58.40 per share in lieu of their shares being extinguished in accordance with the Order.
Resident Shareholders:
The company will pay the amount after deducting 7.5% TDS to the eligible shareholders.
Non- Resident Shareholders:
The company will pay the amount after deducting 20% TDS to the eligible shareholders.